Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

	Dec '19	Dec '20	Dec '21
asset turnover
cash per share	0.58 -	5.73 895.08%	16.25 183.67%
company equity multiplier	-0.17 -	-1.44 769.69%	1.05 172.79%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1.02 -	0.99 3.57%	0.99 0.84%
effective tax rate		-0.00 -	-0.00 71.91%
enterprise value multiple	-19.61 -	-11.18 43.00%	-7.29 34.78%
fixed asset turnover
free cash flow per share	-0.75 -	-1.27 69.37%	-2.97 134.58%
gross profit margin
interest coverage	-280.42 -	-376.50 34.26%	-135.43 64.03%
inventory turnover
long term debt to capitalization
net income per ebt	1 -	1.00 0.02%	1.00 0.01%
net profit margin
operating cash flow per share	-0.75 -	-1.27 69.28%	-2.97 134.70%
operating profit margin
payables turnover
pretax profit margin
price fair value	-4.24 -	-3.17 25.27%	1.48 146.63%
receivables turnover
return on assets	-1.28 -	-0.18 85.94%	-0.19 4.42%
return on capital employed	-1.82 -	-0.19 89.40%	-0.20 2.83%
return on equity	0.21 -	0.26 22.24%	-0.20 176.01%
total debt to capitalization

COM:IMAGOBIO

Imago BioSciences, Inc.

Last Close

36.01

10/01 21:00

Volume Today

138.13K

Avg: -

Preview